

Table S7 Regression analyses of 3-year all-cause and CVD-related mortality with Kaplan–Meier and cumulative incidence function estimates for 3-year mortality (cohort 2, incident HF population)

	<i>N</i> (N=6,522)	All-cause mortality Median survival, days ^a	CVD-related mortality Median survival, days ^b	3-year All-cause Mortality ^{c,d}	3-year CVD-related mortality ^{d,e}
18–54	395	–	–	9.7% (6.5%,13.0%)	3.7% (2.0%,6.3%)
55–64	652	–	–	15.7% (12.6%,18.7%)	7.1% (5.1%,9.5%)
65–74	1,460	–	–	18.3% (16.0%,20.5%)	7.6% (6.2%,9.2%)
75–84	2,228	1,799	–	28.6% (26.4%,30.8%)	12.4% (10.9%,14.0%)
≥85	1,787	997	–	52.9% (50.1%,55.8%)	27.9% (25.6%,30.2%)
Sex					
Women	3,024	1,796	–	31.7% (29.8%,33.6%)	16.3% (14.9%,17.8%)
Men	3,498	–	–	28.4% (26.6%,30.1%)	12.8% (11.6%,14.1%)
HF diagnosis setting					
Primary	1,558	–	–	19.5% (17.0%,21.9%)	11.0% (9.3%,12.9%)
Secondary	4,964	1,799	–	33.1% (31.6%,34.5%)	15.5% (14.4%,16.6%)
HF phenotype					
HFpEF	826	1,746	–	34.8% (31.1%,38.4%)	14.0% (11.5%,16.7%)
HFrEF	1,536	–	–	25.5% (23.1%,28.0%)	13.1% (11.3%,15.0%)
Unknown	4,160	–	–	30.5% (28.9%,32.2%)	15.1% (13.9%,16.3%)
NT-proBNP level, pg/mL					
0–300	369	–	–	12.0% (8.3%,15.7%)	5.6% (3.4%,8.6%)
301–1,000	946	–	–	22.4% (19.3%,25.5%)	10.9% (8.8%,13.3%)

1,001–3,000	1,813	1,799	–	25.9% (23.5%,28.2%)	12.7% (11.0%,14.5%)
>3,000	2,253	1,626	–	39.6% (37.2%,42.0%)	19.2% (17.4%,21.0%)
Year of HF diagnosis					
2010	1,392	–	–	32.8% (30.3%,35.3%)	15.3% (13.5%,17.3%)
2011	1,644	–	–	29.1% (26.8%,31.3%)	14.0% (12.4%,15.8%)
2012	1,661	–	–	–	–
2013	1,825	–	–	–	–

^aPatients are censored at emigration (loss to follow-up) and at end of follow-up (31 December 2014).

^bPatients are censored at emigration, at death due to non-CVD causes and at end of follow-up (31 December 2014).

^cKaplan–Meier estimates of mortality (1–survival).

^dEnd of follow-up restricted to 1 year after second observed HF diagnosis.

^ecumulative incidence function estimates of mortality (1–survival).

Abbreviations: CI, confidence interval; CVD, cardiovascular disease; HF, heart failure; HR, hazard ratio, NT-proBNP, N-terminal pro-B-type natriuretic peptide; SHR, sub-distribution hazard ratio.